PharmaTimes has reported that the European Commission has approved a triple combination antihypertensive with aliskiren, amlodipine and hydrochlorothiazide (Rasitrio). According to the report, the approval is based on the results of a phase III trial involving 1,181 patients which showed that the triple combination produced statistically significant blood pressure reductions compared to dual combinations of the individual components of the product. Detailed statistical data are not available in this report.